GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SK Bioscience Co Ltd (XKRX:302440) » Definitions » Other Operating Expense

SK Bioscience Co (XKRX:302440) Other Operating Expense : ₩66,115 Mil (TTM As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is SK Bioscience Co Other Operating Expense?

SK Bioscience Co's Other Operating Expense for the three months ended in Mar. 2025 was ₩19,916 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2025 was ₩66,115 Mil.

SK Bioscience Co's quarterly Other Operating Expense increased from Sep. 2024 (₩10,588 Mil) to Dec. 2024 (₩24,139 Mil) but then declined from Dec. 2024 (₩24,139 Mil) to Mar. 2025 (₩19,916 Mil).

SK Bioscience Co's annual Other Operating Expense increased from Dec. 2022 (₩39,321 Mil) to Dec. 2023 (₩43,140 Mil) and increased from Dec. 2023 (₩43,140 Mil) to Dec. 2024 (₩57,156 Mil).


SK Bioscience Co Other Operating Expense Historical Data

The historical data trend for SK Bioscience Co's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SK Bioscience Co Other Operating Expense Chart

SK Bioscience Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Operating Expense
Get a 7-Day Free Trial 18,814.12 33,074.11 39,320.55 43,139.65 57,156.09

SK Bioscience Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10,956.40 11,472.76 10,588.42 24,138.52 19,915.51

SK Bioscience Co Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩66,115 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SK Bioscience Co Other Operating Expense Related Terms

Thank you for viewing the detailed overview of SK Bioscience Co's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


SK Bioscience Co Business Description

Traded in Other Exchanges
N/A
Address
310, Pangyo-ro, Bundang-gu, Gyeonggi-do, Seongnam-si, KOR, 13494
SK Bioscience Co Ltd is a South Korean pharmaceutical company. It is engaged in the manufacturing and developing of vaccine. The company has registered SKYCellflu prefilled syringe (PFS), the first cell culture influenza vaccine in Korea, followed by the licensure of SKYCellflu Quadrivalent prefilled syringe and 13-valent Pneumococcal Conjugate Vaccine. Further it has several other vaccines under development and clinical trials including recombinant rotavirus vaccine. In addition, the development of new typhoid conjugate vaccine and innovative pneumococcal vaccine is ongoing in collaboration with external partners.

SK Bioscience Co Headlines

No Headlines